Notice2022-23054
Agency Information Collection Activities: Submission for OMB Review; Comment Request
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
October 24, 2022
Issuing agencies
Health and Human Services DepartmentSubstance Abuse and Mental Health Services Administration
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 204 (Monday, October 24, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 204 (Monday, October 24, 2022)]
[Notices]
[Pages 64242-64243]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-23054]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Agency Information Collection Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and Mental Health Services
Administration (SAMHSA) will publish a summary of information
collection requests under Office of Management and Budget (OMB) review,
in compliance with the Paperwork Reduction Act (44 U.S.C. chapter 35).
To request a copy of these documents, email or call the SAMHSA Reports
Clearance Officer at <a href="/cdn-cgi/l/email-protection#dab9bba8b6b5a9f4bda8bbb2bbb79aa9bbb7b2a9bbf4b2b2a9f4bdb5ac"><span class="__cf_email__" data-cfemail="761517041a1905581104171e171b3605171b1e0517581e1e0558111900">[email protected]</span></a> or (240) 276-0361.
Proposed Project: Program Evaluation for Prevention Contract (PEPC)--
Strategic Prevention Framework for Prescription Drugs (SPF-Rx)
Evaluation (OMB No. 0930-0377)--Revision
The Substance Abuse and Mental Health Services Administration's
(SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ)
aims to complete a cross-site evaluation of SAMHSA's Strategic
Prevention Framework for Prescription Drugs (SPF-Rx). SPF-Rx is
designed to address nonmedical use of prescription drugs as well as
opioid overdoses by raising awareness about the dangers of sharing
medications and by working with pharmaceutical and medical communities
on the risks of overprescribing. The SPF-Rx program aims to promote
collaboration between
[[Page 64243]]
states/tribes and pharmaceutical and medical communities to understand
the risks of overprescribing to youth ages 12-17 and adults 18 years of
age and older. The program also aims to enhance capacity for, and
access to, Prescription Drug Monitoring Program (PDMP) data for
prevention purposes. This request for data collection includes a
revision from previously approved OMB instruments.
The SPF-Rx program's indicators of success are reductions in opioid
overdoses, reductions in prescription drug misuse, and improved use of
PDMP data. Data collected through the tools described in this statement
will be used for the national cross-site evaluation of SAMHSA's SPF-Rx
program. This package covers continued data collection through 2025.
The Program Evaluation for Prevention Control (PEPC) team will
systematically collect and maintain an Annual Reporting Tool (ART) and
Grantee and Community Level Outcomes data modules submitted by SPF-Rx
grantees through the online Data Management System (DMS).
SAMHSA is requesting approval for data collection for the SPF-Rx
cross-site evaluation with the following instruments:
<bullet> Annual Reporting Tool (ART)--The ART is a survey
instrument collected yearly to monitor state, tribal entity, and
community-level performance, and to evaluate the effectiveness of the
SPF-Rx program. This tool is completed by grantees and subrecipient
community project directors and provides process data related to
funding use and effectiveness, organizational capacity, collaboration
with community partners, data infrastructure, planned intervention
targets, intervention implementation, evaluation, contextual factors,
training and technical assistance (T/TA) needs, and sustainability.
<bullet> Grantee-and Community-Level Outcomes Modules--These
modules collect data on key SPF-Rx program outcomes, including opioid
prescribing patterns and provider use of PDMP. Grantees will provide
outcomes data at the grantee level for their state, tribal area, or
jurisdiction, as well as at the community level for each of their
subrecipient communities.
<bullet> Grantee-Level Interview--This qualitative interview will
be administered at the end of the evaluation to obtain information from
the grantee project directors on their programs, staffing, populations
of focus, infrastructure, capacity, lessons learned, and collaboration.
Annualized Data Collection Burden by Year
----------------------------------------------------------------------------------------------------------------
Number of Responses per Total number Hours per Total burden
Instrument respondents respondent of responses response hours
----------------------------------------------------------------------------------------------------------------
Annual Reporting Tool........... \a\ 110 1 110 4 440
\b\ 21 1 21 3 63
Grantee-Level PDMP Outcomes \b\ 21 1 21 2.5 52.5
Module.........................
Community-Level PDMP Outcomes \b\ 21 5.2 110 1.25 137.5
Module.........................
Grantee-Level Interview......... \b\ 21 1 21 1.5 31.5
-------------------------------------------------------------------------------
FY2023...................... 131 .............. 283 .............. 724.5
----------------------------------------------------------------------------------------------------------------
Annual Reporting Tool........... \a\ 110 1 110 4 440
\b\ 21 1 21 3 63
Grantee-Level PDMP Outcomes \b\ 21 1 21 2.5 52.5
Module.........................
Community-Level PDMP Outcomes \b\ 21 5.2 110 1.25 137.5
Module.........................
Grantee-Level Interview......... \b\ 0 N/A N/A 1.5 N/A
-------------------------------------------------------------------------------
FY2024...................... 131 .............. 283 .............. 693
----------------------------------------------------------------------------------------------------------------
Annual Reporting Tool........... \a\ 110 1 110 4 440
\b\ 21 1 21 3 63
Grantee-Level PDMP Outcomes \b\ 21 1 21 2.5 52.5
Module.........................
Community-Level PDMP Outcomes \b\ 21 5.2 110 1.25 137.5
Module.........................
Grantee-Level Interview......... \b\ 21 1 21 1.5 31.5
-------------------------------------------------------------------------------
FY2025...................... 131 .............. 283 .............. 724.5
----------------------------------------------------------------------------------------------------------------
\a\ Community subrecipient respondent.
\b\ Grantee respondent.
Written comments and recommendations for the proposed information
collection should be sent within 30 days of publication of this notice
to <a href="http://www.reginfo.gov/public/do/PRAMain">www.reginfo.gov/public/do/PRAMain</a>. Find this particular information
collection by selecting ``Currently under 30-day Review--Open for
Public Comments'' or by using the search function.
Carlos Graham,
Reports Clearance Officer.
[FR Doc. 2022-23054 Filed 10-21-22; 8:45 am]
BILLING CODE 4162-20-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on October 24, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.